Humaid Al-Shamsi: Outcomes of HSCT from Matched Related Donors in Pediatric Patients
Humaid Al-Shamsi, Chief Executive Officer at Burjeel Cancer Institute (BCI), shared on LinkedIn:
“Excited to share our Burjeel Cancer Institute (BCI) 15th publication in 2025!
Our latest study, ‘Outcomes of Hematopoietic Stem Cell Transplantation (HSCT) from Matched Related Donors in Pediatric Patients: Insights from a Single Center in the United Arab Emirates’.
This research showcases the remarkable outcomes at Burjeel Cancer Institute at Burjeel Medical City since pediatric HSCT services began in 2022, with a 100% survival rate and 0% transplant-related mortality in the first 25 cases. These results underscore the power of our tailored conditioning regimens and BCI multidisciplinary care.
Thank you Dr Zainul Aabideen and for leading this publication.
A heartfelt thanks to our dedicated BMT team and the patients and families who made this possible.”
Title: Outcomes of Hematopoietic Stem Cell Transplantation (HSCT) From Matched Related Donors in Pediatric Patients: Insights From a Single Center in the United Arab Emirates
Journal: Cureus
Authors: Zainul Aabideen Kanakkande Kandy, Sagar Nivargi, Bina Chaudhary, Mohammed Ramzan, Fahed Abdullah, Fouzia Aboobacker, Charbel Khalil, Fulvio Porta, Lawrence Faulkner, Humaid Alshamsi
More posts featuring Humaid Al-Shamsi on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023